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Abstract: Investigating cold argon plasma (CAP) for medical applications is a rapidly growing,
innovative field of research. The controllable supply of reactive oxygen and nitrogen species through
CAP has the potential for utilization in tumour treatment. Maxillofacial surgery is limited if tumours
grow on vital structures such as the arteria carotis. Here CAP could be considered as an option for
adjuvant intraoperative tumour therapy especially in the case of squamous cell carcinoma of the head
and neck. Further preclinical research is necessary to investigate the efficacy of this technology for
future clinical applications in cancer treatment. Initially, a variety of in vitro assays was performed
on two cell lines that served as surrogate for the squamous cell carcinoma (SCC) and healthy tissue,
respectively. Cell viability, motility and the activation of apoptosis in SCC cells (HNO97) was
compared with those in normal HaCaT keratinocytes. In addition, induction of apoptosis in ex vivo
CAP treated human tissue biopsies of patients with tumours of the head and neck was monitored
and compared to healthy control tissue of the same patient. In response to CAP treatment, normal
HaCaT keratinocytes differed significantly from their malignant counterpart HNO97 cells in cell
motility only whereas cell viability remained similar. Moreover, CAP treatment of tumour tissue
induced more apoptotic cells than in healthy tissue that was accompanied by elevated extracellular
cytochrome c levels. This study promotes a future role of CAP as an adjuvant intraoperative tumour
therapy option in the treatment of head and neck cancer. Moreover, patient-derived tissue explants
complement in vitro examinations in a meaningful way to reflect an antitumoral role of CAP.
Keywords: cold argon plasma; head and neck squamous cell carcinoma; apoptosis; keratinocytes;
plasma medicine
1. Introduction
Squamous cell carcinoma (SCC) is the second most frequent type of skin cancer after basal cell
carcinoma [1] and arises frequently in the head and neck area. Treatment is multifaceted, challenging
and has to be performed on an individualised basis. Complexity and variability of different tumour
entities demand specific cancer therapies including surgery, chemotherapy or radiotherapy. Standard
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therapy for most of the extra- and intraoral tumours is based on a radical surgery combined with
stage-based neo-adjuvant and / or adjuvant chemotherapy or radiation. Yet to date, patients suffering
from advanced head and neck cancer are still faced with a poor prognosis, if cancer cells are infiltrating
sensitive anatomical structures such as the skull base, the ocular bulb or main arteries that cannot
be resected safely (one example is given in Figure 1). To reduce chemotherapy side effects and
improve clinical outcomes, additional intraoperative antitumor treatment tools are urgently needed
to complement current therapies. Cold atmospheric pressure plasma (CAP) at temperatures within
physiological ranges offers versatile options for biological and medical applications in general [2–5]
and recently was promoted to aid in cancer therapy [6–9].
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Figure 1. Axial (left) and coronal (right) cross sectional radiographic images of a lymph node 
metastasis (*) of the left cervical level IIb of a 38 years old male patient suffering from an advanced 
squamous cell carcinoma of the oral cavity at retromolar region (UICC stadium IVa). Primary 
carcinoma has been surgically removed with a surrounding safety margin. Due to the metastasis´ 
closeness to the vascular wall of the arteria carotis interna (#) and externa (+), a surgical removal could 
not be performed with a safety distance. Biopsy testing for the presence of possible remaining tumour 
cells at the vascular wall could not be performed. So, possible remaining tumour cells can be the 
reason for tumour recurrence or metastasis. 
Plasma is often referred to as the fourth state of matter and is considered the most reactive one. 
Therapeutic effects are achieved in a single treatment modality due to the combined action of 
ultraviolet radiation, charged particles, reactive oxygen species (ROS), reactive nitrogen species 
(RNS) and electrical fields [2,10]. First results on the compatibility and application of CAP were 
gained in the field of dermatology as well as in plastic and aesthetic medicine [11–17]. CAP 
applications can range from anti-inflammatory [18] and antimicrobial [19,20] to tissue stimulatory 
[21] therapeutic effects. In addition, recently Vandamme et al. and others have shown that CAP can 
inhibit tumour growth by ROS-mediated apoptosis [6,22,23]. Moreover, there are indications that 
CAP works selective for cancer cells by killing them more effectively than non-neoplastic cells [24,25]. 
Fig re 1. Axial (left) and coronal (right) cross sectional radiographic images of a lymph node metastasis
(*) of the left cervical level IIb of a 38 years old male patient suffering from an advanced squamous cell
carcinoma of the oral cavity at r tr molar region (UICC st dium IVa). Primary carcinoma has been
surgically remov d with a surrounding safety margin. Due to the metastasis´ closeness to the vascular
wall of the arteria carotis interna (#) and xterna (+), a surgical removal could not be performed with a
safety distance. Biopsy testing for he presence of possible remaining tumour cells at the vascular wall
ould not be performed. So, possible r maining tumour cell can b the reason for tumour recurrenc
or metastasis.
l is often refe red to as the fourth state of matter and is considered the most reactive
on . Therapeuti effects re achieved in a single treatment modality due to the combined action f
ltr i l t radiation, charged particles, reactive oxygen species (ROS), reactive nitrogen specie (RNS)
and electrical fields [2,10]. First results on the compatibility and application of CAP were gained in th
field of dermatology as w ll as in plastic and aesthetic medicine [11–17]. CAP applications can range
from anti-infl mmatory [18] d a ti icrobial [19,20] to tissue stimulatory [21] therapeutic effects.
In addition, recently Vandamme et al. and others h ve shown that CAP can inhibit tumour growth by
ROS-mediated apoptosis [6,22,23]. Moreover, there are indications that CAP works s lective for cancer
cells by killing them more effectively than on-neoplastic cells [24,25]. Consequently, the concept of
using CAP in the manner of intra-operative neo-adjuvant tumour therapy is to treat remaining cancer
cells after conventionally tumour bulk reduction by surgery as far as possible. Hence, CAP offers the
potential for new adjuvant tumour therapies [6,8].
In this study, the response of healthy and tumour cells of head and neck cancer to CAP exposure
was addressed by means of cell viability, cell cycle changes and motility behaviour, including possible
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target proteins and apoptosis. In addition, excised tissue samples of head and neck squamous cell
carcinoma and healthy neighbouring tissue of the oral cavity of the same patient were investigated for
induction of apoptosis and secreted proteins with antitumor activity. We were able to demonstrate
a significant impact of CAP against malignant cells in tissue and partially in vitro. These insights
are reason for hope that CAP could be an effective tool to support radical resection of head and
neck cancers.
2. Methods
2.1. Cell Culture
Non-malignant HaCaT keratinocytes and malignant HNO97 (head and neck squamous cell
carcinoma of the oral cavity) were employed in this study (Cell Line Service, Eppelheim, Germany).
Both cell types were maintained in Roswell Park Memorial Institute (RPMI) 1640 cell culture medium
supplemented with 8% heat inactivated foetal bovine serum, 100 IU/mL penicillin, 100 µg/mL
streptomycin and 2 mM glutamine in a humidified atmosphere at 37 ◦C and 5% CO2 (all PAN Biotech,
Aidenbach, Germany).
2.2. Tissue Samples
Non-malignant and malignant tissue samples were collected from 10 patients (6 men, 4 women;
mean age 59.9 years; median age 56 years; age range 43 to 75 years) with histologically proven cancers
of the maxillofacial region [9 squamous cell carcinoma of the floor of the mouth (n = 5), the cheek
(n = 2), the tongue (n = 1), the retromolar region (n = 1) and one adenocarcinoma of the maxillary
sinus] during their preoperative inpatient care at the clinic of maxillofacial surgery / plastic surgery at
the University Medicine Greifswald. Specimen were immediately immersed in William’s medium
(Biochrom, Cambridge, UK) supplemented with 0.25 µg/mL amphotericin B, 100 IU/mL penicillin and
10 µg/mL streptomycin (Corning, Amsterdam, The Netherlands). Subsequently, the tissue samples
were treated with CAP and kept in serum free William’s E medium supplemented with 100 IU/mL
penicillin/ 10 µg/mL streptomycin, 2 mM glutamine, 10 µg/mL insulin and 10 ng/mL hydrocortisone
(Sigma Aldrich, Taufkirchen, Germany) for 24 h, as described elsewhere [21,26]. All volunteers gave
their written and informed consent to participate in the laboratory study and permitted the non-invasive
collection of tissue samples for additional histological examinations after radical tumour surgery.
2.3. Plasma Source and Plasma Treatment
The certified medical device kINPen MED® (neoplas tools, Greifswald, Germany) was used to
realize plasma treatment. It consists of two electrodes, a pin type high voltage electrode inside a
ceramic capillary and one grounded electrode. It generates a radiofrequency signal of about 1 MHz
and a voltage amplitude of 2–3 kV. The discharge is switched on and off at a frequency of 2.5 kHz
(50:50). Argon gas (Air Liquide, Kornwestheim, Germany) flow rate was set to 5 standard litres per
minute. The plasma was generated at the tip of the pin type electrode and expanded about 1 cm to the
surrounding air outside the capillary.
In case of monolayer cells, the culture medium was exposed to the plasma effluent for the indicated
length of time and plasma-treated medium was immediately added to the adherent cells whose cell
culture medium was thereby replaced. By contrast, tissue samples were directly exposed to the plasma
effluent at a distance of about 8 mm from the capillary outlet as previously described [27]. Untreated
tissue samples served as negative control. The gas temperature at working distance is 35–39 ◦C.
2.4. Cell Viability
A test for cell viability was performed with a resazurin-based assay (Alamar Blue®Assay) and was
evaluated as described in detail earlier [28]. Briefly, 3500 cells were seeded per well in 96-well plates
and allowed to attach overnight. Plasma-treated cell culture medium (150 µL) was added to each well
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and incubated for 72 h. Plates were washed twice with Hanks buffered saline solution prior to the
addition of 100 µM resazurin (Alfa Aesar, Kandel, Germany) in complete cell culture medium without
phenol red. Formation of resorufin was observed at λex 530 nm and at λem 590 nm using a microplate
reader (Tecan, Männedorf, Switzerland). Cell viability was calculated as percentage of control (100%).
To investigate apoptosis in cell culture, CellEvent caspase 3/7 detection reagent (Life Technologies,
Carlsbad, CA, USA) was added to cells 6 h after exposure to plasma-treated medium. Cell fluorescence
was acquired at λex 485 nm and λem 535 nm using the same microplate reader.
2.5. Cell Cycle Analyses
One million HaCaT and HNO97 cells, respectively, were seeded into 60 mm cell culture dishes.
CAP-treated cell culture medium was added and incubated for 24 h. Cells were detached by incubation
with trypsin/EDTA. Cells were transferred into FACS tubes, washed in PBS, fixed and permeabilised in
ice-cold ethanol (70% v/v) overnight at 4 ◦C. Subsequently, cells were washed, and DNA was stained
with 4,6-Diamidin-2-phenylindol (Sigma, Taufkirchen, Germany) in FACS-buffer for 1 h. DNA content
analysis was carried out using flow cytometry (Gallios; Beckman-Coulter, Brea, CA, USA).
2.6. Cell Motility Assay
1 × 106 cells in 5 mL of fully supplemented RPMI 1640 were seeded in 60 mm cell culture dishes.
Just before the cell culture medium was replaced by CAP treated medium a diagonal scratch was
created using a 10 µL pipette tip. Dishes were placed on a heated and CO2-gassed microscope stage
(Zeiss, Jena, Germany). Microscopic images were taken at 24 h. The initial gap size was set to 0% and
gap closure was calculated as percent.
2.7. DNA Fragmentation
As a marker for apoptosis in tissue, DNA fragmentation was detected by terminal dUTP nick-end
labelling (TUNEL), employing a commercially available fluorescein kit (in situ cell death detection
kit, Roche applied science, Mannheim, Germany). Positive cells were evaluated using fluorescence
microscopy (Zeiss, Jena, Germany) and an open source image processing software (ImageJ, version
1.47, NIH, USA).
2.8. Cytochrome C Measurements
Twenty-four hours after CAP treatment, supernatant of cultured tissue samples were collected
and stored at −80 ◦C until they were subjected to cytochrome c ELISA, according to the manufacturer’s
instructions (eBioscience, Affymetrix, ViennaAustria). Concentrations were normalized to total
extracellular protein content (Biorad, Heracles, CA, USA).
2.9. Cytokine Detection
The same supernatant medium was analysed for tumour necrosis factor α (TNFα), interferon γ
(INFγ), interleukin (IL) 10 and IL22 using a bead-based assay, according the manufacturer’s instructions
(BioLegend, San Diego, CA, USA). At least 300 beads per analyte were acquired utilizing a CytoFlex
flow cytometer (Beckman-Coulter, Brea, CA, USA).
2.10. Global Protein Expression
Global protein expression was carried out as previously described [28]. Briefly, peptides were
separated using nanoliquid chromatography (Dionex Ultimate 3000; PepMap RSLC column, 75 µm
ID/15 cm length, Sunnyvale, CA, USA) and eluates were ionized by electrospray ionization and
analysed by high resolution mass spectrometry (positive mode, QExactive, Thermo, Waltham, MA,
USA). Data processing was done using Proteome Discoverer 1.4 (Thermo). Protein candidates were
selected upon their involvement in pathways of metabolisms and proliferation as well as on statistical
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criteria (≥ ± 2.0-fold expression). Data were also analysed with Ingenuity Pathway Analysis software
(IPA, Qiagen, Hilden, Germany) and free web-based applications (PANTHER and Uniprot.org).
2.11. Statistics
Statistical analysis was performed using Prism 6 (GraphPad software, version 6.05, San Diego,
CA, USA). Two-way analysis of variances (ANOVA) with Dunnett correction (comparison to untreated
control for each cell type separately) was employed to statistically describe cell motility data, whereas
matched one-way ANOVA with Dunnett correction was applied to caspase, cell cycle, cytochrome c
and cytokine data detection. The level of significance was displayed on the plots as follows: p < 0.05 (*),
p < 0.01 (**), p < 0.001 (***).
3. Results
3.1. Examinations on Cultured Cells
3.1.1. CAP Reduced Viability in Normal and Tumour Cells
CAP expels reactive species which are known to confer cytotoxic effects in eukaryotic cells
in a concentration dependent manner. HaCaT keratinocytes and HNO97 cells were exposed to
plasma-treated medium and their metabolic activity was reduced in a treatment time-dependent
manner (Figure 2A). In order to compare both cell lines an IC50 value was calculated by sigmoid
regression of relative resorufin fluorescence as a function of treatment time. The viability after
incubation in CAP treated medium between both cell lines revealed very similar IC50 values; that is,
31 s for HaCaT keratinocytes and 36 s for HNO97 cells (Figure 2A). This suggests a comparable
sensitivity towards plasma-induced redox stress for these two cell types of epidermal origin.
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response to cold tm spheric pressure plasma (CAP) treated cell culture medium. (A). Cell viability is
reduced af er CAP reatment in both cell lines similarly. Formation of resorufin is plotted as a funct on
of tr atment time (log scale). Both curves summarize two individual experiments with 12 single
measuremen s. 50% of v able cells (IC50) are reached after CAP treatme t for 31 s and 36 s, respectively.
Cell cycle nalyses revealed a G2/M-arr st in HaCaT k ratinocy s and HNO97 cancer cells by CAP
t ated cel culture medium. Representative histograms for control (red line) and 150 s treatment
time ( lue line) r disp ayed for HaCaT keratinocytes (B) and for HNO97 cancer cells (D). Both,
HaCaT keratinocytes and HNO97 cells responded by a G2/M arrest with increasing CAP exposure time,
m st pronounced t 80 s and 150 s (C and E).
3.1.2. Cell Cycle Arrest after CAP Treatment in HaCaT Keratinocytes and in HNO97 Cells
Th distribution of DAPI-stained cells was analysed ccording to the histogram plot of DNA
content against cell numbers of both cell lines (representative examples are shown in Figure 2B,D.
In HaCaT keratinocytes, CAP treated medium (80 s and 150 s) caused a significantly elevated level of
cells in the G2/M phase concomitant with a decrease in the proportion of cells in G0/G1 (Figure 2C).
Of untreated cells 49% were in G0/G1 phase while this portion decreased significantly to 37% after
150 s CAP treatment. At the same time, cells in the G2/M phase increased from 18.6% to 30% for 150 s
of CAP exposure. The impact of CAP treated medium on HNO97 cell cycle progression was less
pronounced and revealed a decrease from 65% to 57.7% in the G0/G1 phase and a significant increase
of 14.5% to 19.3% in the G2/M phase (Figure 2E).
3.1.3. CAP Exposure Activated Caspase in HNO97 Cancer Cells and HaCaT Keratinocytes
Both cell lines, normal an head and eck squamous cell carcinom cells, sign fican ly activated
caspase 3/7 when incubated in CAP treated medium. (Figure 3). A treatment time dependent activation
of caspase 3/7 was present after CAP exposure in both cell types. Hence, significant activation of
Appl. Sci. 2019, 9, 2061 7 of 16
caspase 3/7 levels occurred after the longest treatment times of 80 s and 150 s (Figure 3). This result
indicates a non-selective induction of apoptotic events in both cell lines.
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Figure 3. Activation of caspase 3/7 by CAP treated cell culture medium in HaCaT keratinocytes
and HNO97 cells. CAP treatment took place for 0, 20, 40, 80 and 150 s and incubation followed for
6 h. Activation is detected as relative fluorescent units (RFU). Each bar resulted of three individual
measurements (mean +SD).
3.1.4. Motility of Malignant Cells Was Significantly Impaired by CAP Treatment
Motili y and migratio w re an lysed n 2D-setup following incubatio with CAP-treated
culture medium comparing non-malignant and head and neck squamous cell carcinoma cells. Into a
confluent layer of cells, the scratch width was measured at start (0 h), after 12 h and 24 h following
addition of CAP-treated culture medium. By comparison, untreated HNO97 cells moved significantly
faster (Figure 4A) than untreated HaCaT keratinocytes (Figure 4B); gap closure within 24 h constituted
50% and 20%, respectively (Figure 4C). CAP treatment on HaCaT cells had no significant influence for
the tested treatment time regimen (Figure 4C). However, in head and neck squamous cell carcinoma
cells gap closure was significantly reduced from 50% in untreated cells to 20% after CAP treatment.
In summary, CAP treatment caused a significant impairment in the motility behaviour of HNO97
while HaCaT keratinocytes remained nearly unaffected.
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Figure 4. Cell motility was tested in HNO97 cancer cells and HaCaT keratinocytes in response to CAP
treatment. Representative microscopic photographs of a scratch assay are depicted for (A) HNO97
and (B) HaCaT keratinocytes. Cell motility was evaluated as gap closure in % of the initial distance
after 12 and 24 h, respectively and displayed as bar grap ) for both cell lines. HaC T keratinocytes
are significantly less motile compared to their malignant counterpart HNO97 (compare both ctrl).
Addition of CAP treated medium reduced cell motility significantly in HNO97 (empty bars) while
HaCaT keratinocytes are not affected (dark bars). The assay was performed at least in triplicates. Bars
represent mean + SD. Magnification × 100.
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3.1.5. Total Protein Expression Modulated by CAP Treatment Reflect Changes in Cell Motility
Several thousand proteins were detected in the investigated cell lines with a false discovery rate of
1% (5445 HaCaT/8258 HNO97), allowing a materially oversight of cell processes at sampling. Of these,
229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized
in the Table 1 below.
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP treatment.
Protein changes are indicated as: up to two-fold increased →↑; two-fold increased ↑; 5 to 12-fold
increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓;
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Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
not changed.
Protein Name Uniprot ID HaCaT HNO97 Function
Ki67 P46013
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treatment. Protein changes are indicated as: up to tw -fold incr ased →↑; two-fold incre sed ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of eroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
→↑ Proliferation
NQO1 P15559 →↑
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3.1.5. Total Protei  Expression Modulated by CAP Treatme t Reflect Changes in Cell Motility  
Several thousand proteins were detected in the investigated cell lines with a false discovery rate 
of 1 % (5445 aCaT/8258 HNO97), allowing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes are indicate  as: up to two-fold increased →↑; two-fold increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑  Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
Nuclear factor erythroid 2-related factor 2 (NRF2)
related signalling
TMX2 Q9Y320 ↑
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nd (B) HaCaT keratinocytes. Cell motility was evaluated as gap closure in % of the initial distance
after 12 and 24h, respectively and displayed as bar graph (C) for both cell lines. HaCaT ker tinocytes
are signific ntly les  motile compared to their malignant counterpa t HNO97 (compare both ctrl).
Addition of CAP treated medium reduced cell motility significantly in HNO97 (empty bars) while 
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3.1.5. Total Protein Expression Modulated by CAP Treatment Reflect Changes in Cell Motility  
Several thousand proteins were d tected in the investigated cell lines with a false discovery rat
f 1 % (5445 HaCaT/8258 HNO97), allowing a materially oversight of ell processes at sampling. Of
these, 229 HaCaT and 419 HNO97 prote s are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes are indicated as: up to two-fold increased →↑; two-fold increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
NRF2 related signalling
GSTM3 P21266 ↑
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3.1.5. Total Protein Modula by CAP Treatment Reflect Change   Cell Motility  
Several thousand proteins were detected in the investigated cell lines with a false discovery rate 
of 1 % (5445 HaCaT/8258 97), all wing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes are in i ated as: up to tw -fold increased →↑; tw -fold increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related ignalling 
TMX2 Q9Y320 ↑  NRF2 related signalling 
GSTM3 P21266 ↑  NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elim natio  of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
NRF2 related signalling
PRDX1,2,4,6 Q06830
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of 1 % (5445 HaCaT/8258 HNO97), allowing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes re indicated as: up to two-fold increased →↑; two-fold increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑  Nuclea  factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑ ↔ NRF2 related sig alling 
GSTM3 P21266 ↑  NRF2 related signalling 
PRDX1,2,4,6 06830 ↔ ↔ R dox regulatio , elimi ation of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulatio , interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
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3.1.5. Total Protei  Expression Modulat d by CAP Treatm nt Reflect Changes in Cell Motility  
Several housand prot ins were detected in the investigated cell lines with a false discovery rate 
of 1 % (5445 aCaT/8258 97), llowing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (acco ding to Uniprot gene 
n ology annotations) with 185 proteins detected in both cell ty es. Select d proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in norm l and malignant cells 3 h and 24 h after CAP 
treatment. Protei  ch nges are in i ated as: up to tw -fold increase  →↑; tw -fold increased ↑; 5 to 
12-fold increase ↑↑; two-fold decrease  ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑  ucl ar facto  erythroid 2-related factor 2 
(NRF2) related sig alling 
TMX2 320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑  NRF2 elated signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox re ulation, elimination of peroxides 
SBNO2 9Y2G9  ↑ Transcriptio al co- r gulat on, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
Redox regulation, elimination of peroxides
SB O2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin signalling
ILKAP Q9H0C8 ↑↑
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3.1.5. Total Prot in Ex ression Modul ted by CAP Treatment Reflect C anges in Cell Motility  
Several thousand proteins were d t cted in the investigated cell lines with a false discovery rat
f 1 % (5445 HaCaT/8258 HNO97), allowing a materially oversight of ell processes at sampling. Of
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in th  table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 4 h after CAP 
treatment. Protein changes are indicated as: up to two-fold increased →↑; two-fold increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 320 ↑  NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
Cell adhesion and growth factor signalling
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis
ROCK O75116 →↑ ↓↓ Regulation of actin cytoskeleton, cell adhesion and
motility
CTTB2 Q8WZ74 ↑↑ →↑ Cytoskeleton rearrangement, cell migration and motility
CFA20 Q9Y6A4 ↑↑
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Figure 4. Cell motility was tested in HNO97 cancer cells and HaCaT keratinocyt  i  response o CAP 
treatment. Representative micro copic photographs of a scratch ssay are depicted f r (A) HNO97 
and (B) HaCaT keratinocytes. Cell motility was evaluated as gap closure in % of the initial distance 
after 12 and 24h, respectively and displayed as bar graph (C) for both cell lines. HaCaT keratinocytes 
are significantly less motile compared to their malignant counterpart HNO97 (compare both ctrl). 
Addition of AP treated medium reduced cell motility significantly in HNO97 (empty bars) while 
HaCaT ker tinocytes are not affecte  (dark bars). The assay was performed at least in triplicates. Bars 
represent mean +SD. Magnification x100 . 
3.1.5. Tot l Protein Expression Modulated by CAP Treatment R flect Changes in Cell Motility  
Sev ral thousand proteins were detected in the investigated cell lines with a false discovery rate 
of 1 % (5445 HaCaT/8258 HNO97), llowing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration ( ccording to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes are indicated as: up to two-fold increased →↑; two-f ld increased ↑; 5 t  
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreas d ↓↓; ↔ not ch nged.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Fu ction 
Ki67 P46 13 ↔ →↑ Pro iferation 
NQO1 P 5559 ↔ Nuclear f ct r erythroid 2-related factor 2 
(NRF2) related signalling 
TMX2 320 ↑ ↔ NRF2 related signalling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
Cell motility
SRGP2 O75044 n.d. ↑ Cell migration inhibition, actin dynamics
ELMO3 Q96BJ8
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Figure 4. Cell motility was tested in HNO97 cancer cells and HaCaT keratinocytes in respo se t  CAP 
treatment. Repres ntative microscopi  photograph  of a scratch assay are depicted for (A) HNO97 
and (B) HaCaT k rati ocytes. Cell motil ty was evaluated as gap closure in % of the initial distance 
after 12 and 24h, respectively and displayed as bar graph (C) for both cell li es. HaCaT keratinocytes 
are significantly less motile c mpared to heir malignant counterpart HNO97 (compare both ctrl). 
Additio  of CAP treated medium reduc d ell motility significantly in HNO97 (empty bars) while 
HaCaT k ratinocytes are not ffected (dark bars). Th  ass y was performed at least in triplicates. Bars 
repr sent mean +SD. Magnif cation x100 . 
3.1.5. To al Protein Expr ssion Mo ulated by CAP Treatmen  Re lect Chang in Cell M ility  
Several thousand proteins were detected in the investigated cell lines with a f lse dis overy rate
of 1 % (5445 HaCaT/8258 HNO97), allowing a materially oversight of ce l processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (according to Uniprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant c lls 3 h and 24 h after CAP 
treatment. Protein changes are indicated as: up to two-fold increased →↑; two- old increased ↑; 5 to 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Functi  
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑ ↔ Nuclear factor rythroid 2-rel ted factor 2 
(NRF2) r lated signalling 
TMX2 9Y320 ↑ ↔ NRF2 related sig alling 
GSTM3 P21266 ↑ ↔ NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
↓ Cell motility
CASP8/10 Q14790/Q92851
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Figure 4. Cell motility was tested in HNO97 cancer cells and HaCaT keratinocytes in response to CAP 
treatment. Represe tative microscopic photographs of a scr tch ssay are depicted for (A) HNO97
and (B) HaCaT kerati ocytes. Cell motility was evaluate as gap closure in % of the initial distance
after 12 and 24h, respectively and displayed as bar graph (C) for both cell lines. HaCaT keratinocytes 
are significantly less motile compared to their alignant counterpart HNO97 (co pare both ctrl). 
Addition of CAP treated medium reduced cell motility significantly in HNO97 (empty bars) while 
HaCaT keratinocytes are not affected (dark bars). The assay was performed at least in triplicates. Bars 
represent mean +SD. Magnification x100 . 
3.1.5. Total Protein Expression Mo ulated by CAP Treatment Re lect Cha g s in Cell M ility  
Several thousand proteins were detected in the investigated cell lines with a false discovery r te 
of 1 % (5445 HaCaT/8258 97), allowing a materially oversight of cell processes at sampling. Of 
these, 229 HaCaT and 419 HNO97 proteins are connected to cell migration (accor in  to U iprot gene 
ontology annotations) with 185 proteins detected in both cell types. Selected proteins are summarized 
in the table below.  
Table 1. Expression of selected proteins in normal and malignant cells 3 h and 24 h after CAP 
treatment. Protein changes are in i ated as: up to tw -fold increased →↑; tw -fold increased ↑; 5 o 
12-fold increased ↑↑; two-fold decreased ↓; 5-12-fold decreased ↓↓; ↔ not changed.  
Protein 
Name 
Uniprot ID HaCaT HNO97 Function 
Ki67 P46013 ↔ →↑ Proliferation 
NQO1 P15559 →↑  Nuclear factor rythroid 2-rel ted factor 2 
(NRF2) related signalling 
TMX2 Q9Y320 ↑  NRF2 related signalling 
GSTM3 P21266 ↑  NRF2 related signalling 
PRDX1,2,4,6 Q06830 ↔ ↔ Redox regulation, elimination of peroxides 
SBNO2 Q9Y2G9 ↑↑ ↑ Transcriptional co- regulation, interleukin 
signalling  
ILKAP Q9H0C8 ↑↑ ↔ Cell adhesion and growth factor signalling 
AAMP Q13685 →↑ ↓ Cell migration, angiogenesis 
C 
↑ Pro-apoptotic caspases
3.2. Examinations on Tissue Specimen
Induction of apoptosis by CAP treatment was superior in tumour tissue compared with healthy
mucosal tissu .
Following CAP triggered cytotoxicity and induction of early apoptotic events in cultured cells we
next extended this view to biopsies of human non-malignant mucosa and squamous cell carcinoma of
the head and neck area and investi ated differences between these tissues after CAP treatment (3 min).
The number of apoptotic cells was evaluated in situ in the tumour tissue and in healthy mucosal
tissue of the same pati nt. In healthy tissu , DNA fragmentation after CAP exposure indicative for
apoptosis was marginal. Low numbers of TUNEL-positive cells were counted, namely 2.58% versus
0.79% at median in untreated s mples and CAP treated tissue specimens, respectively (Figure 5).
In contrast, the tissue samples of head and neck squamous cell carcinoma displayed a significantly
elevated median number of apoptotic cells of 5.6% compared to untreated tumour tissue (1.4%). In this
context, it is noteworthy to mention that individual responsiveness varies (Figure 5).
To strengthen the finding of induced apoptosis by CAP in tissue samples, the supernatant medium
was analysed for cytochrome c and selected cytokines. As a marker for cell death, cytochrome c is
released by mitochondria upon induction of apoptosis. Initially, the tumour tissue even without CAP
treatment revealed a much higher amount of cytochrome c than the corresponding healthy tissue
(1729 ng per mg protein versus 385 ng per mg protein) (Figure 6). However, the CAP treatment
triggered apoptotic pathways and the cytochrome c concentration raised significantly to as high as
5155 ng per mg protein in the supernatant of the tumour tissue (three-fold increase). Strikingly this
was not the case for the corresponding healthy tissue. Here the same CAP treatment regimen led to a
mean cytochrome c content of 698 ng per mg protein (1,8-fold increase) (Figure 6).
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Figure 5. Induction of apoptotic cells by CAP application in tumour tissue in situ. TUNEL-positive 
cells were detected in several specimen of squamous cell carcinoma as well as in healthy tissue 
donated by the same patient. Results are displayed as scatter dot plot with a line at median. While 
healthy tissue revealed only very few TUNEL-positive cells after CAP exposure for 3 min the number 
increased in tumour tissue. Note the inter individual variance. 
 
Figure 5. Induction of apopt tic cells by CAP applicatio in tumour tissue in situ. TUNEL-positive
cells were detected in several specimen of squamous cell carcinoma as well as in healthy tissue donated
by the same patient. Results are displayed as scatter dot plot with a line at median. While healthy
tissue revealed only very few TUNEL-positive cells after CAP exposure for 3 min the number increased
in tumour tissue. Note the inter individual variance.
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Taken together, the results revealed that tissue of healthy and malignant origin differed significantly
in their response to CAP treatment. Induction of apoptosis occurred predominantly in tumour tissue
while in healthy tissue the impact of CAP was not significant. This finding inspired us to look for
mediators like cytokines in conditioned medium in a preliminary test. Tumour necrosis factor α
(TNFα), interferon γ (IFNγ), interleukin (IL) 10 and IL22 were detected and results are presented
in Figure 6B–E. Due to small sample size and inter individual variances, only a tendency can be
derived (Figure 6B–E). Strikingly higher concentrations of IL22 were released from healthy tissue
while INFγ, TNFα and IL10 were found predominantly in tumour tissue of the corresponding patient
(Figure 6B,C,D). CAP treatment tends to increase the levels of TNFα and IFNγ in tumour tissue but
showed no effect in corresponding healthy tissue.
4. Discussion
The delivery of CAP-generated ROS and RNS through the liquid environment to cells changes
the redox environment, which ultimately may induce cytotoxic effects [29,30]. With respect to cancer
treatment, it is widely accepted that CAP-generated ROS and RNS are the main agents to induce cell
death and apoptosis in cancer cells [6,24,31]. After CAP application an increasing number of apoptotic
cancer cells positively correlate with an increased concentration of nitric oxide (NO), ROS and lipid
peroxidation products [32]. Others demonstrated that CAP induces apoptosis via ROS and dysfunction
of mitochondrial membranes [23]. In addition, autophagy has been discussed as another way of cell
death after CAP exposure especially in primary cells [33]. This illustrates the great potential of CAP
in the therapeutic concept of tumour treatment on the basis of ROS/RNS generation. In this context
eliminating cancer cells by pharmacological ROS insults has also been developed independent of CAP
technology [34]. The mode of action of some chemotherapeutic agents employs partly the production
of ROS and therefore enhances their cytotoxic effectiveness (e.g., cisplatin or bleomycin) [35–38].
Even more so, a synergistic effect of gemcitabine and CAP in killing pancreatic tumour cells has been
described recently [39].
Squamous cell carcinoma of the head and neck can grow in very close vicinity to vital structures
(Figure 1), hence pose a surgical challenge for resection. Therefore, this study investigated CAP
application as a potential adjuvant tool in the treatment of squamous cell carcinoma in this region.
Unique advantages of the CAP application are the accessibility of localized areas and upon this time
no known side effects [5,9].
In our study the certified medical device kINPen MED was employed to generate CAP.
The therapeutic concept of the kINPen is based on the generation of ROS and RNS (RONS) [40].
Recently, a beneficial effect of this argon plasma jet treatment on head and neck cancer was documented
in a retrospective clinical follow-up study by Metelmann and colleagues [41]. Several repeated cycles
of CAP application for only one minute lead to partial remission of the tumour in 36% of the cases
but prominent histological alterations were absent. Herein ex vivo treated tissue biopsies revealed
an increased number of apoptotic cells within the tissue and elevated levels of cytochrome c in the
extracellular liquid, pointing to profound apoptotic cell damage. This is in good agreement with clinical
findings in head and neck squamous cell carcinoma patients [9]. In our approach, the distribution of
TUNEL-positive cells was rather randomly dispersed throughout the tissue sections (data not shown),
pointing to a non-cell-cell-contact-based mechanism. Contrary, results from Partecke et al. showed
more dying cells in the outermost layers of treated pancreatic carcinoma tissue concomitant with
reduced proliferation [42]. The therapeutic application of CAP in cancer treatment requires certain
selectivity towards malignant cells. In our experimental setup we could show stronger induction of
apoptosis in tumour tissue in situ compared to healthy tissue. In order to follow events in a 2D cell
culture setup, two corresponding cell lines were selected, normal HaCaT keratinocytes and HNO97
derived from a human squamous cell carcinoma of the head and neck. However, the cell lines used
revealed very little difference with respect to induction of apoptotic events after CAP exposure. Hence,
the selectivity was not established in these in vitro tests. This may be due to the simple homogeneous
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cell population. Further the sensitivity towards CAP varies among HNSCC and non-malignant
cell lines and the underlying molecular composition should be considered for future examinations.
By contrast, others found that CAP selectively impairs some cell lines of head and neck squamous cell
carcinoma also through non-apoptotic pathways [24,43]. The idea of CAP selectivity for cancer cells
has been debated recently and a selective CAP effect on tumour cells has been ascribed to divergent
metabolic features, anti-oxidative capacity or erroneous signalling processes [24,25,44,45].
In addition to cytotoxic events, the cells motility also was investigated. To preclude a risk, HaCaT
and HNO97 cells were tested for their ability to move into a scratch. In this model, CAP treatment
significantly decreased cell motility in squamous cell carcinoma cells only but not in non-malignant
keratinocytes. Protein expression profiles support this finding by identifying reduced expression
of several proteins related to cytoskeleton rearrangement, motility and cell migration. Cell motility
as well as cell-cell-adhesion are both closely related to the expression of E-cadherin among other
adhesion molecules. Previous research showed that the expression of E-cadherin negatively correlates
with the progression of oral squamous cell carcinoma and dedifferentiation [46]. Interestingly,
elevated E-cadherin and EGFR expression level were earlier detected after CAP treatment in HaCaT
keratinocytes [47] but not in HNO97 cells.
Notably, the expression of angio-associated migratory cell protein (AAMP) also correlated with
the migratory activity in several cell types, including smooth muscle cells and endothelial cells [48].
The expression of AAMP was reduced after CAP treatment in HNO97, whereas its expression slightly
increased in HaCaT cells depending on the treatment intensity and time point [49]. We also observed
that AAMP was secreted into the extracellular compartment and acts upon neighbouring cells,
potentially contributing to remote effects of CAP.
Interestingly, for non-malignant murine fibroblasts a change in integrin expression concomitant
with reduced motility after CAP exposure was reported earlier [50]. Moreover, we found that also
SK-MEL-147 human melanoma cells displayed significantly decreased cell motility when subjected to
CAP-treated medium [51]. This effect was correlated with alterations in the cytoskeleton, such as actin
fibre rearrangement, and hence agrees well with alterations in non-melanoma skin cancer cells.
Regarding redox signalling events our results are in accordance with Weiss et al., who described
unaltered protein levels of peroxiredoxin 1 and 2 after CAP exposure [52].
Moreover, our results illustrate the high complexity and heterogeneity of tumour tissue consisting
of extracellular matrix, immune cells and epithelial cells. This led us to investigate extracellular cytokines
after CAP exposure that function as mediators. Our results merely detected four immunomodulatory
cytokines with different concentrations in healthy versus tumour tissue. Especially IL10 has been
detected at higher levels in squamous cell carcinoma by others [53] and is in accordance with our
finding. Considering the central role of INFγ in keratinocyte apoptosis and TNFα’s potential to
increase this effect, it is noticeable that our approach revealed an increased concentration of INFγ and
TNFα after CAP treatment in tumour tissue [54]. This is in good agreement with detected elevated
cytochrome c levels after CAP treatment. Effects mediated by second messenger like the AAMP protein
or the interleukins and cellular signalling in response to CAP application remain largely elusive but
require more attention in future approaches.
Intriguingly variations between HaCaT keratinocytes and HNO97 squamous cell carcinoma
cells were rather minor in our 2D cell culture approach whereas patient derived tissue revealed very
differential responses towards CAP treatment. This finding highlights the need to employ clinically
relevant model systems for further preclinical investigations of CAP.
5. Conclusions
• Controlled application of CAP may provide a means to kill malignant cells.
• CAP application may be a promising adjuvant treatment option to eliminate minimal residual
cancer cells after radical surgery of carcinoma of the head and neck area.
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• Investigations towards the underlying mechanism remain to be addressed under consideration of
accompanying cell types.
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